29.04.2021 08:09:00
|
Interim report January-March 2021
STOCKHOLM, April 29, 2021 /PRNewswire/ --
- Revenue amounted to €317.2m (€238.8m), an increase of 32.8% with an organic growth of 39.7%.
- Operating profit (EBIT) was €41.6m (€6.4m), representing an operating margin of 13.1% (2.7%).
- Net profit amounted to €26.3m (€-2.5m), which represents a net profit margin of 8.3% (-1.0%).
- EBITDA was €65.5m (€29.0m), an increase of 125.6%. EBITDA margin was 20.6% (12.2%).
- EBITDAaL amounted to €52.9m (€16.8m), corresponding to an EBITDAaL margin of 16.7% (7.0%).
- Net cash flow from operating activities was €57.7m (€36.6m).
- Basic/diluted earnings per share were €0.174
(€-0.006). - Covid-19-pandemic had a net positive impact on operating performance.
REVENUE AND EARNINGS
€ millions (€m) |
Q1 2021 |
Q1 2020 |
Growth |
FY 2020 |
Revenue |
317.2 |
238.8 |
33% |
997.8 |
Operating profit (EBIT) |
41.6 |
6.4 |
550% |
61.3 |
Operating profit margin |
13.1% |
2.7% |
6.1% | |
Net profit |
26.3 |
-2.5 |
1,152% |
27.3 |
Net profit margin |
8.3% |
-1.0% |
2.7% | |
Basic/diluted earnings per share, € |
0.174 |
-0.006 |
3,000% |
0.182 |
EBITDA |
65.5 |
29.0 |
126% |
157.5 |
EBITDA margin |
20.6% |
12.2% |
15.8% | |
EBITDAaL |
52.9 |
16.8 |
215% |
108.5 |
EBITDAaL margin |
16.7% |
7.0% |
10.9%
| |
EBITA |
44.1 |
8.9 |
396% |
76.9 |
EBITA margin |
13.9% |
3.7% |
7.7% |
Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.
This report has not been subject to review by the Company's auditor.
This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CEST) on 29 April 2021. This interim report and other information about Medicover is available at www.medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com
Conference call: A conference call for analysts and investors will be held today at 09.30 CEST. To listen in please register here. To ask questions please dial in and use code: 8975934
SE: 08-566 184 67
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167
Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2020, Medicover had revenue of EUR 998 million and more than 32,000 employees. For more information, go to www.medicover.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medicover/r/interim-report-january-march-2021,c3336192
The following files are available for download:
https://mb.cision.com/Main/15662/3336192/1409468.pdf | Interim report January-March 2021 |
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Medicover AB Registered Shs -B-mehr Nachrichten
29.10.24 |
Ausblick: Medicover Registered B präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
15.10.24 |
Erste Schätzungen: Medicover Registered B gewährt Anlegern Blick in die Bücher (finanzen.net) | |
24.07.24 |
Ausblick: Medicover Registered B verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
10.07.24 |
Erste Schätzungen: Medicover Registered B stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |